MedTrace Logo

Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan

NCT01281371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2013-06-27

No results posted yet for this study

Summary

Due to the withdrawal of Thelin (Sitaxentan) in December 2010 all patients with pulmonary hypertension treated with Sitaxentan need to be switched to an alternative therapy. This study will observe in which way the change of medication - in the clinical routine, without exception in charge of the treating physician - affects clinical and laboratory parameters and patient's quality of life.

Conditions

  • Hypertension, Pulmonary

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Walter E. Haefeli, Prof. Dr. med. · Department of Clinical Pharmacology and Pharmacoepidemiology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281371 on ClinicalTrials.gov